Acoramidis ATTR Cm denied as experimental or investigational by Aetna?

Aetna's specific coverage criteria for acoramidis attr cm are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna May Label Acoramidis Experimental for ATTR-CM — and How to Appeal

An "experimental" or "investigational" denial means Aetna has determined — under its internal clinical-policy criteria — that the evidence base for acoramidis does not yet meet its threshold for coverage as an established treatment. This is a particularly important denial type to challenge, because regulatory approval status and an insurer's internal evidence threshold are not the same standard. For the current FDA-approval status and the approved indication of acoramidis, consult the FDA-approved prescribing information directly.

Note: If acoramidis is FDA-approved for the indication being treated, that approval is a powerful and direct counter to an experimental denial. Your appeal should lead with this.

## Why This Denial Is Appealable

Under ACA §2719 and ERISA §503, experimental denials are subject to full-and-fair internal review. Crucially, the ACA external-review process specifically requires that independent review organizations (IROs) apply generally accepted standards of medical practice — not the insurer's internal policy — when evaluating experimental/investigational denials. This makes external review a particularly valuable pathway for this denial type. The external-review window is typically within four months of the final internal denial, with an expedited option available.

## Your Appeal Timeline

• Internal appeal: File within 180 days of the denial (check the exact deadline on your Explanation of Benefits).
• External review: Request within four months of the final internal denial; the IRO will apply independent clinical standards.
• Expedited track: Available when delay would seriously jeopardize health — ATTR-CM is a progressive disease, which may support an expedited request.

## Documentation to Gather

1. Diagnosis confirmation: Full cardiac workup confirming ATTR-CM diagnosis, including subtype (wild-type or hereditary variant) and current disease stage/functional class. 2. FDA approval and labeling: A copy of or reference to the current FDA-approved prescribing information for acoramidis, confirming the approved indication. Your pharmacist or prescriber can provide this. 3. Prescriber medical-necessity letter: A letter from the treating cardiologist explaining why acoramidis is the appropriate therapy for this patient, noting FDA approval status and alignment with current cardiology society guidance. 4. Applicable guideline reference: Request that your cardiologist note whether the ACC, AHA, or other relevant professional society has issued guidance or statements supporting use of acoramidis for ATTR-CM. 5. Prior treatment history: Documentation of earlier-line treatments tried, their outcomes, and why acoramidis is the appropriate current intervention.

## Criteria-Mapping Structure

Obtain Aetna's Clinical Policy Bulletin for acoramidis or TTR stabilizers. For each criterion used to classify the drug as experimental, map it to a rebuttal:

| Experimental Criterion Cited | Rebuttal Evidence | |---|---| | FDA approval status | [FDA label confirming approval + indication] | | Evidence standard not met | [Prescriber letter citing guideline support] | | Indication matches denied claim | [Chart diagnosis vs. FDA-approved indication] | | Medical necessity for this patient | [Cardiologist's clinical rationale] |